Diabetes, Cardiovascular & Renal Complications
SMi is excited to present their inaugural Diabetes, Cardiovascular & Renal Complications conference. This is the perfect forum to assess the changing spectrum of therapies in development for treating diabetes.
Join leading academics at the forefront of improving basic pre-clinical, translational and clinical research and senior executives from leading companies at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London
Gain the knowledge and insights you require on how to utilise RAAS inhibition to preserve renal function and delay cardiovascular disease progression
Hear from academic and industry teams on pre-clinical target validation for hyperkalaemia and renal fibrosis
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Develop strategies to utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Harness the "new" paradigm for diabetic nephropathy endpoints to improve your clinical trial design
Learn about compliance with new FDA and EU guidelines when conducting risk-benefit assessments
.SMi’s unique program brings together the latest research from those at the head of attenuating complications arising from hyperglycaemia, dyslipidaemia, atherosclerosis and fibrosis. This event is not to be missed!
5 reasons you should attend this extraordinary event include:
For more information contact Farhaana Rahman on +44 0207 827 6186 or visit http://www.smi-online.co.uk/diabetes-conference56.asp